Pelin YILDIZ, Ganime ÇOBAN, Nurcan UNVER, Seval TURNA, Cevper ERSÖZ, Nur BUYUKPİNARBASİLİ, Zuhal GÜCİN

The association of GLUT-1, Galectin 3 and Claudin 1 staining with the type of renal tumors

Aim: The mechanism of carcinogenesis and prognostic parameters of renal cell carcinomas(RCC) exhibiting an increasing incidencetrend are still obscure. Even though new tumors types are identified, diagnostic difficulty is even experienced occasionally for themost common tumor types. Various immunohistochemical and molecular-genetic studies are conducted for tumor type identificationand prognostic evaluation. The present study examined glucose transporter protein (GLUT-1), galectin-3 that is associated with cellgrowth, differentiation, proliferation, adhesion, angiogenesis and apoptosis, and Claudin 1, a transmembrane protein of intercellulartight junctions, immunohistochemically for the most commonly encountered renal tumors. The staining patterns were compared interms of Fuhrman nuclear grade, stage, metastasis, and demographic data.Material and Methods: Methods: The study consisted of a total of 99 renal tumor cases including 40 Clear Cell Renal Cell Carcinoma(CCRCC), 22 Chromophobe Renal Cell Carcinoma (CrRCC), 16 Oncocytoma and 19 Papillary Renal Cell Carcinoma (PRCC) cases.Results: Overexpression of GLUT-1 was observed in 92.5% of CCRCC cases and 36.8% of PRCC cases whereas the loss of expressionwas observed in CrRCC and Oncocytoma. Claudin-1 was seen in 77.5% of the CCRCCs, 45.4% of the CrRCCs, 81.25% of theoncocytomas and 84.2% of the PRCCs. Galectin-3 was present in 90% of the CCRCCs, 81% of the CrRCCs, 50% of the oncocytomasand 21% of the PRCCConclusion: Diffuse membranous staining pattern was observed for GLUT-1 in case of CCRCC, however, no correlation withprognostic parameters was noticed. Claudin-1 expression was observed in high nuclear grade tumors. Thus, it may be regarded asa poor prognostic factor. Galectin 3 expression was observed in the tumors with sarcomatoid differentiation.

PDF

___

1. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913- 24.
2. Sawada N, Murata M, Kikuchi K, et al. Tight junctions and human diseases. Med Electron Microsc 2003;36:147-56.
3. Sakaki M, Fukumori T, Fukawa T, et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 2010;57:152-7.
4. Xu Y, Li C, Sun J, et al. Antitumor effects of galectin-3 inhibition in human renal carcinoma cells. Exp Biol Med (Maywood) 2016;241:1365-73.
5. Wang JL, Werner EA, Laing JG, et al. Nuclear and cytoplasmic localization of a lectin-ribonucleoprotein complex. Biochem Soc Trans 1992;20:269-74.
6. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-62.
7. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
8. Gill IS, Aron M, Gervais DA, et al. Clinical practice. Small renal mass. N Engl J Med 2010;362:624-34.
9. Sun M, Lughezzani G, Jeldres C, et al. A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. Eur Urol 2009;56:775- 81.
10. Shin HI, Kim BH, Chang HS, et al. Expression of claudin-1 and -7 in clear cell renal cell carcinoma and its clinical significance. Korean J Urol 2011;52:317-22.
11. Langbein L, Grund C, Kuhn C, et al. Tight junctions and compositionally related junctional structures in mammalian stratified epithelia and cell cultures derived therefrom. Eur J Cell Biol 2002;81:419-35.
12. Lee DB, Huang E, Ward HJ. Tight junction biology and kidney dysfunction. Am J Physiol Renal Physiol 2006;290:20-34.
13. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-93.
14. Gong Y, Hou J. Claudins in barrier and transport functionthe kidney. Pflugers Arch-Eur J Physiol 2017;469: 105-13.
15. Süren D, yıldırım M, Sayiner A, at al. Expression of claudin 1, 4 and 7 in thyoid neoplams. Oncology Letters 2017;13:3722- 26.
16. Soini Y. Expression o claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 2005;46:551-60.
17. Resnick MB, Konkin T, Routhier J, et al. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 2005;18:511-18.
18. Warrier S, Sellinger C, Beith JM, et al. Claudin-1 as a novel transcriptional target of hedgehog signaling and a predictor for outcome in breast cancer. 2013 ASCO Annual Meeting Proceedings J Clin Oncol. 31: Abstract 2013;1053.
19. Sun B, Yao Y, Pei B, et al. Claudin-1 correlates with poor prognosis in lung adenocarcinoma. Thoracic Cancer 2016;7:556-63.
20. Vırman J, Soını Y, Kujala P, at al. Claudins as Prognostic Factors for Renal Cell Cancer. Antıcancer Research 2014;34:4181-88.
21. Fritzsche F, Oelrich B, Johannsen M, et al. Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res 2008;14:7035-42.
22. Lechpammer M, Resnick MB, Sabo E, et al. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol 2008;21:1320-29.
23. men w, martın t, ruge f, et al. expression of Claudins in Human Clear Cell Renal Cell Carcinoma. Cancer Genomics Preteomics 2015;12:1-8.
24. Desmedt V, Desmedt S, Delange JR, et al. Galectin-3 in renal pathology: more than just an innocent bystander? Am J Nephrol 2016;43:305-17.
25. Delacour D, Cramm-Behrens CI, Drobecq H, et al. Requirement for galectin-3 in apical protein sorting. Curr Biol 2006;16:408-14.
26. Zhao Q, Duckworth CA, Wang W, et al. Peanut agglutinin appearance in the blood circulation after peanut ingestion mimics the action of endogenous galectin-3 to promote metastasis by interaction with cancer-associated MUC1. Carcinogenesis 2014;35:2815-21.
27. Von Klot CA, Kramer MW, Peters I, et al: Galectin-1 and galectin-3 mRNA expression in renal cell carcinoma. BMC Clin Pathol 2014;14:15.
28. Dancer J, truong L, Zhai Q, et al. Expression of Galectin-3 in renal neoplasms. Arch Pathol Lab Med 2010;134:90-4.
29. Merseburger AS, Kramer MW, HennenlotterJ, et al: Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 2008;26:637-42.
30. Szablewski L. Expression of glucose transporters in cancers. Biochimica et Biophysica Acta 2013;1835:164-69.
31. Ozcan A, Shen SS, Zhai QJ, Expression of GLUT1 in primary renal tumors morphologic and biologic implications. Am J Clin Pathol 2007;128:245-54.
32. Nagase Y, Takata K, Moriyama N, et al. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995;153:798-801.
33. Miyakita H, Tokunaga M, Onda H, et al. Significance of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002;9:15-8.